Genomic landscape of intracranial meningiomas

Journal of Neurosurgery

Volumn 125, Issue 3, 2016, Pages 525-535

  Bi, Wenya Linda ^a,c   Abedalthagafi, Malak ^a,e   Horowitz, Peleg ^a   Agarwalla, Pankaj K ^b,c   Mei, Yu ^a   Aizer, Ayal A ^a   Brewster, Ryan ^a   Dunn, Gavin P ^d   Al Mefty, Ossama ^a   Alexander, Brian M ^a   Santagata, Sandro ^a   Beroukhim, Rameen ^c   Dunn, Ian F ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e KING FAHAD MEDICAL CITY   (Saudi Arabia)

Author keywords

Genomics; Meningioma; Molecular taxonomy; Oncology; Precision medicine; Targeted therapy; Tumor classification; Tumor progression

Indexed keywords

ANTINEOPLASTIC AGENT;

CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER GENETICS; CANCER GRADING; CARCINOGENESIS; CHROMOSOME 22; CHROMOSOME ABERRATION; COPY NUMBER VARIATION; FAMILIAL CANCER; GENOMICS; GENOTYPE PHENOTYPE CORRELATION; GERMLINE MUTATION; HISTOPATHOLOGY; HISTORY OF MEDICINE; HUMAN; MENINGIOMA; NEUROFIBROMATOSIS TYPE 2; NEUROPATHOLOGY; NEXT GENERATION SEQUENCING; PERSONALIZED MEDICINE; PRIORITY JOURNAL; REVIEW; SOMATIC MUTATION; BRAIN TUMOR; GENETICS; MUTATION; PATHOLOGY;

BRAIN NEOPLASMS; HUMANS; MENINGEAL NEOPLASMS; MENINGIOMA; MUTATION; PRECISION MEDICINE;

EID: 84987623376     PISSN: 00223085     EISSN: 19330693     Source Type: Journal    
DOI: 10.3171/2015.6.JNS15591     Document Type: Review

References (104)

1. Aavikko M, Li SP, Saarinen S, Alhopuro P, Kaasinen E, Morgunova E, et al: Loss of SUFU function in familial multiple meningioma. Am J Hum Genet 91:520-526, 2012
2. Abedalthagafi MS, Merrill PH, Bi WL, Jones RT, Listewnik ML, Ramkissoon SH, et al: Angiomatous meningiomas have a distinct genetic profile with multiple chromosomal polysomies including polysomy of chromosome 5. Oncotarget 5:10596-10606, 2014
3. Al-Mefty O, Kadri PA, Pravdenkova S, Sawyer JR, Stangeby C, Husain M: Malignant progression in meningioma: documentation of a series and analysis of cytogenetic findings. J Neurosurg 101:210-218, 2004
4. Al-Mefty O, Topsakal C, Pravdenkova S, Sawyer JR, Harrison MJ: Radiation-induced meningiomas: clinical, pathological, cytokinetic, and cytogenetic characteristics. J Neurosurg 100:1002-1013, 2004
5. Bacci C, Sestini R, Provenzano A, Paganini I, Mancini I, Porfirio B, et al: Schwannomatosis associated with multiple meningiomas due to a familial SMARCB1 mutation. Neurogenetics 11:73-80, 2010
6. Backer-Grøndahl T, Moen BH, Torp SH: The histopathological spectrum of human meningiomas. Int J Clin Exp Pathol 5:231-242, 2012
7. Baser ME, Evans DG, Jackler RK, Sujansky E, Rubenstein A: Neurofibromatosis 2, radiosurgery and malignant nervous system tumours. Br J Cancer 82:998 2000 (Letter)
8. Bello MJ, Amiñoso C, Lopez-Marin I, Arjona D, Gonzalez-Gomez P, Alonso ME, et al: DNA methylation of multiple promoter-associated CpG islands in meningiomas: relation-ship with the allelic status at 1p and 22q. Acta Neuropathol 108:413-421, 2004
9. Bleeker FE, Felicioni L, Buttitta F, Lamba S, Cardone L, Rodolfo M, et al: AKT1(E17K) in human solid tumours. Oncogene 27:5648-5650, 2008
10. Boström J, Cobbers JM, Wolter M, Tabatabai G, Weber RG, Lichter P, et al: Mutation of the PTEN (MMAC1) tumor suppressor gene in a subset of glioblastomas but not in meningiomas with loss of chromosome arm 10q. Cancer Res 58:29-33, 1998
11. Boström J, Meyer-Puttlitz B, Wolter M, Blaschke B, Weber RG, Lichter P, et al: Alterations of the tumor suppressor genes CDKN2A (p16(INK4a)), p14(ARF), CDKN2B (p15(INK4b)), and CDKN2C (p18(INK4c)) in atypical and anaplastic meningiomas. Am J Pathol 159:661-669, 2001
12. Brastianos PK, Horowitz PM, Santagata S, Jones RT, McKenna A, Getz G, et al: Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations. Nat Genet 45:285-289, 2013
13. Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR, et al: The somatic genomic landscape of glioblastoma. Cell 155:462-477, 2013
14. Büschges R, Boström J, Wolter M, Blaschke B, Weber RG, Lichter P, et al: Analysis of human meningiomas for aberrations of the MADH2, MADH4, APM-1 and DCC tumor suppressor genes on the long arm of chromosome 18. Int J Cancer 92:551-554, 2001
15. Büschges R, Ichimura K, Weber RG, Reifenberger G, Collins VP: Allelic gain and amplification on the long arm of chromosome 17 in anaplastic meningiomas. Brain Pathol 12:145-153, 2002
16. Cai DX, Banerjee R, Scheithauer BW, Lohse CM, Kleinschmidt-Demasters BK, Perry A: Chromosome 1p and 14q FISH analysis in clinicopathologic subsets of meningioma: diagnostic and prognostic implications. J Neuropathol Exp Neurol 60:628-636, 2001
17. Carvalho LH, Smirnov I, Baia GS, Modrusan Z, Smith JS, Jun P, et al: Molecular signatures define two main classes of meningiomas. Mol Cancer 6:64 2007
18. Castellano F, Ruggiero G: Meningiomas of the posterior fossa. Acta Radiol Suppl 104:1-177, 1953
19. Chen HJ, Liang CL, Lu K, Lin JW, Cho CL: Implication of telomerase activity and alternations of telomere length in the histologic characteristics of intracranial meningiomas. Cancer 89:2092-2098, 2000
20. Chen L, Tanriover G, Yano H, Friedlander R, Louvi A, Gunel M: Apoptotic functions of PDCD10/CCM3, the gene mutated in cerebral cavernous malformation 3. Stroke 40:1474-1481, 2009
21. Christiaans I, Kenter SB, Brink HC, van Os TA, Baas F, van den Munckhof P, et al: Germline SMARCB1 mutation and somatic NF2 mutations in familial multiple meningiomas. J Med Genet 48:93-97, 2011
22. Clark VE, Erson-Omay EZ, Serin A, Yin J, Cotney J, Ozduman K, et al: Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. Science 339:1077-1080, 2013
23. Cuevas IC, Slocum AL, Jun P, Costello JF, Bollen AW, Riggins GJ, et al: Meningioma transcript profiles reveal deregulated Notch signaling pathway. Cancer Res 65:5070-5075, 2005
24. Curto M, McClatchey AI: Nf2/Merlin: a coordinator of receptor signalling and intercellular contact. Br J Cancer 98:256-262, 2008
25. Darr J, Klochendler A, Isaac S, Eden A: Loss of IGFBP7 expression and persistent AKT activation contribute to SMARCB1/Snf5-mediated tumorigenesis. Oncogene 33:3024-3032, 2014
26. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, et al: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031-1037, 2001
27. Du Z, Abedalthagafi M, Aizer AA, McHenry AR, Sun HH, Bray MA, et al: Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma. Oncotarget 6:4704-4716, 2015
28. Durand A, Labrousse F, Jouvet A, Bauchet L, Kalamaridès M, Menei P, et al: WHO grade II and III meningiomas: a study of prognostic factors. J Neurooncol 95:367-375, 2009
29. Durant ST, Paffett KS, Shrivastav M, Timmins GS, Morgan WF, Nickoloff JA: UV radiation induces delayed hyperre-combination associated with hypermutation in human cells. Mol Cell Biol 26:6047-6055, 2006
30. Fontaine B, Rouleau GA, Seizinger BR, Menon AG, Jewell AF, Martuza RL, et al: Molecular genetics of neurofibromatosis 2 and related tumors (acoustic neuroma and meningioma). Ann N Y Acad Sci 615:338-343, 1991
31. Goutagny S, Nault JC, Mallet M, Henin D, Rossi JZ, Kalamarides M: High incidence of activating TERT promoter mutations in meningiomas undergoing malignant progression. Brain Pathol 24:184-189, 2014
32. Goutagny S, Yang HW, Zucman-Rossi J, Chan J, Dreyfuss JM, Park PJ, et al: Genomic profiling reveals alternative genetic pathways of meningioma malignant progression dependent on the underlying NF2 status. Clin Cancer Res 16:4155-4164, 2010
33. Hadfield KD, Smith MJ, Trump D, Newman WG, Evans DG: SMARCB1 mutations are not a common cause of multiple meningiomas. J Med Genet 47:567-568, 2010
34. Hamaratoglu F, Willecke M, Kango-Singh M, Nolo R, Hyun E, Tao C, et al: The tumour-suppressor genes NF2/Merlin and Expanded act through Hippo signalling to regulate cell proliferation and apoptosis. Nat Cell Biol 8:27-36, 2006
35. Harada T, Irving RM, Xuereb JH, Barton DE, Hardy DG, Moffat DA, et al: Molecular genetic investigation of the neurofibromatosis type 2 tumor suppressor gene in sporadic meningioma. J Neurosurg 84:847-851, 1996
36. Herscovici Z, Rappaport Z, Sulkes J, Danaila L, Rubin G: Natural history of conservatively treated meningiomas. Neurology 63:1133-1134, 2004
37. Hollmann TJ, Hornick JL: INI1-deficient tumors: diagnostic features and molecular genetics. Am J Surg Pathol 35:e47-e63, 2011
38. James MF, Han S, Polizzano C, Plotkin SR, Manning BD, Stemmer-Rachamimov AO, et al: NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth. Mol Cell Biol 29:4250-4261, 2009
39. James MF, Stivison E, Beauchamp R, Han S, Li H, Wallace MR, et al: Regulation of mTOR complex 2 signaling in neurofibromatosis 2-deficient target cell types. Mol Cancer Res 10:649-659, 2012
40. Johnson MD, O'Connell MJ, Pilcher W, Reeder JE: Fibroblast growth factor receptor-3 expression in meningiomas with stimulation of proliferation by the phosphoinositide 3 kinase-Akt pathway. J Neurosurg 112:934-939, 2010
41. Johnson MD, Okediji E, Woodard A: Transforming growth factor-beta effects on meningioma cell proliferation and signal transduction pathways. J Neurooncol 66:9-16, 2004
42. Johnson MD, Woodard A, Kim P, Frexes-Steed M: Evidence for mitogen-associated protein kinase activation and transduction of mitogenic signals by platelet-derived growth factor in human meningioma cells. J Neurosurg 94:293-300, 2001
43. Jones DT, Jäger N, Kool M, Zichner T, Hutter B, Sultan M, et al: Dissecting the genomic complexity underlying medulloblastoma. Nature 488:100-105, 2012
44. Kalamarides M, Niwa-Kawakita M, Leblois H, Abramowski V, Perricaudet M, Janin A, et al: Nf2 gene inactivation in arachnoidal cells is rate-limiting for meningioma development in the mouse. Genes Dev 16:1060-1065, 2002
45. Kalamarides M, Stemmer-Rachamimov AO, Niwa-Kawakita M, Chareyre F, Taranchon E, Han ZY, et al: Identification of a progenitor cell of origin capable of generating diverse meningioma histological subtypes. Oncogene 30:2333-2344, 2011
46. Kaley T, Barani I, Chamberlain M, McDermott M, Panageas K, Raizer J, et al: Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review. Neuro Oncol 16:829-840, 2014
47. Kros J, de Greve K, van Tilborg A, Hop W, Pieterman H, Avezaat C, et al: NF2 status of meningiomas is associated with tumour localization and histology. J Pathol 194:367-372, 2001
48. Labauge P, Fontaine B, Neau JP, Bergametti F, Riant F, Blecon A, et al: Multiple dural lesions mimicking meningiomas in patients with CCM3/PDCD10 mutations. Neurology 72:2044-2046, 2009
49. Langford LA, Piatyszek MA, Xu R, Schold SC Jr, Wright WE, Shay JW: Telomerase activity in ordinary meningiomas predicts poor outcome. Hum Pathol 28:416-420, 1997
50. Lawrence MS, Stojanov P, Mermel CH, Robinson JT, Garraway LA, Golub TR, et al: Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 505:495-501, 2014
51. Leuraud P, Dezamis E, Aguirre-Cruz L, Taillibert S, Lejeune J, Robin E, et al: Prognostic value of allelic losses and telomerase activity in meningiomas. J Neurosurg 100:303-309, 2004
52. Liu Y, Pang JC, Dong S, Mao B, Poon WS, Ng HK: Aberrant CpG island hypermethylation profile is associated with atypical and anaplastic meningiomas. Hum Pathol 36:416-425, 2005
53. Lomas J, Amiñoso C, Gonzalez-Gomez P, Eva Alonso M, Arjona D, Lopez-Marin I, et al: Methylation status of TP73 in meningiomas. Cancer Genet Cytogenet 148:148-151, 2004
54. Lomas J, Bello MJ, Arjona D, Gonzalez-Gomez P, Alonso ME, de Campos JM, et al: Analysis of p73 gene in meningiomas with deletion at 1p. Cancer Genet Cytogenet 129:88-91, 2001
55. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al (eds): WHO Classification of Tumours of the Central Nervous System, ed 4. Lyon, France: IARC, 2007
56. Louvi A, Chen L, Two AM, Zhang H, Min W, Günel M: Loss of cerebral cavernous malformation 3 (Ccm3) in neuroglia leads to CCM and vascular pathology. Proc Natl Acad Sci U S A 108:3737-3742, 2011
57. Lusis EA, Watson MA, Chicoine MR, Lyman M, Roerig P, Reifenberger G, et al: Integrative genomic analysis identifies NDRG2 as a candidate tumor suppressor gene frequently inactivated in clinically aggressive meningioma. Cancer Res 65:7121-7126, 2005
58. Mawrin C, Sasse T, Kirches E, Kropf S, Schneider T, Grimm C, et al: Different activation of mitogen-activated protein kinase and Akt signaling is associated with aggressive phenotype of human meningiomas. Clin Cancer Res 11:4074-4082, 2005
59. McDermott U, Downing JR, Stratton MR: Genomics and the continuum of cancer care. N Engl J Med 364:340-350, 2011
60. Mendiola M, Bello MJ, Alonso J, Leone PE, Vaquero J, Sarasa JL, et al: Search for mutations of the hRAD54 gene in sporadic meningiomas with deletion at 1p32. Mol Carcinog 24:300-304, 1999
61. Mérel P, Hoang-Xuan K, Sanson M, Moreau-Aubry A, Bijlsma EK, Lazaro C, et al: Predominant occurrence of somatic mutations of the NF2 gene in meningiomas and schwannomas. Genes Chromosomes Cancer 13:211-216, 1995
62. Morrison H, Sperka T, Manent J, Giovannini M, Ponta H, Herrlich P: Merlin/neurofibromatosis type 2 suppresses growth by inhibiting the activation of Ras and Rac. Cancer Res 67:520-527, 2007
63. Niedermayer I, Feiden W, Henn W, Steilen-Gimbel H, Steudel WI, Zang KD: Loss of alkaline phosphatase activity in meningiomas: a rapid histochemical technique indicating progression-associated deletion of a putative tumor suppressor gene on the distal part of the short arm of chromosome 1. J Neuropathol Exp Neurol 56:879-886, 1997
64. Northcott PA, Korshunov A, Pfister SM, Taylor MD: The clinical implications of medulloblastoma subgroups. Nat Rev Neurol 8:340-351, 2012
65. Ostrom QT, Gittleman H, Farah P, Ondracek A, Chen Y, Wolinsky Y, et al: CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006-2010. Neuro Oncol 15 (Suppl 2):ii1-ii56, 2013
66. Palma L, Celli P, Franco C, Cervoni L, Cantore G: Longterm prognosis for atypical and malignant meningiomas: a study of 71 surgical cases. Neurosurg Focus 2(4):e3, 1997
67. Palma L, Celli P, Franco C, Cervoni L, Cantore G: Longterm prognosis for atypical and malignant meningiomas: a study of 71 surgical cases. J Neurosurg 86:793-800, 1997
68. Perry A, Banerjee R, Lohse CM, Kleinschmidt-DeMasters BK, Scheithauer BW: A role for chromosome 9p21 deletions in the malignant progression of meningiomas and the prognosis of anaplastic meningiomas. Brain Pathol 12:183-190, 2002
69. Perry A, Louis DN, Scheithauer BW, Budka H, von Deimling A: Meningiomas, in Louis DN, Ohgaki H, Wiestler OD, et al (eds): WHO Classification of Tumours of the Central Nervous System, ed 4. Lyon, France: IARC, 2007, pp 164-172
70. Perry A, Scheithauer BW, Stafford SL, Lohse CM, Wollan PC: "Malignancy" in meningiomas: a clinicopathologic study of 116 patients, with grading implications. Cancer 85:2046-2056, 1999
71. Peters N, Wellenreuther R, Rollbrocker B, Hayashi Y, Meyer-Puttlitz B, Duerr EM, et al: Analysis of the PTEN gene in human meningiomas. Neuropathol Appl Neurobiol 24:3-8, 1998
72. Piaskowski S, Rieske P, Szybka M, Wozniak K, Bednarek A, Płuciennik E, et al: GADD45A and EPB41 as tumor suppressor genes in meningioma pathogenesis. Cancer Genet Cytogenet 162:63-67, 2005
73. Reifenberger J, Wolter M, Weber RG, Megahed M, Ruzicka T, Lichter P, et al: Missense mutations in SMOH in sporadic basal cell carcinomas of the skin and primitive neuroectodermal tumors of the central nervous system. Cancer Res 58:1798-1803, 1998
74. Reuss DE, Piro RM, Jones DT, Simon M, Ketter R, Kool M, et al: Secretory meningiomas are defined by combined KLF4 K409Q and TRAF7 mutations. Acta Neuropathol 125:351-358, 2013
75. Riant F, Bergametti F, Fournier HD, Chapon F, Michalak-Provost S, Cecillon M, et al: CCM3 Mutations Are Associated with Early-Onset Cerebral Hemorrhage and Multiple Meningiomas. Mol Syndromol 4:165-172, 2013
76. Riemenschneider MJ, Perry A, Reifenberger G: Histological classification and molecular genetics of meningiomas. Lancet Neurol 5:1045-1054, 2006
77. Rogers L, Barani I, Chamberlain M, Kaley TJ, McDermott M, Raizer J, et al: Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review. J Neurosurg 122:4-23, 2015
78. Rong R, Tang X, Gutmann DH, Ye K: Neurofibromatosis 2 (NF2) tumor suppressor merlin inhibits phosphatidylinositol 3-kinase through binding to PIKE-L. Proc Natl Acad Sci U S A 101:18200-18205, 2004
79. Ruttledge MH, Sarrazin J, Rangaratnam S, Phelan CM, Twist E, Merel P, et al: Evidence for the complete inactivation of the NF2 gene in the majority of sporadic meningiomas. Nat Genet 6:180-184, 1994
80. Sahm F, Bissel J, Koelsche C, Schweizer L, Capper D, Reuss D, et al: AKT1E17K mutations cluster with meningothelial and transitional meningiomas and can be detected by SFRP1 immunohistochemistry. Acta Neuropathol 126:757-762, 2013
81. Sawyer JR, Husain M, Pravdenkova S, Krisht A, Al-Mefty O: A role for telomeric and centromeric instability in the progression of chromosome aberrations in meningioma patients. Cancer 88:440-453, 2000
82. Schmitz U, Mueller W, Weber M, Sévenet N, Delattre O, von Deimling A: INI1 mutations in meningiomas at a potential hotspot in exon 9. Br J Cancer 84:199-201, 2001
83. Sekulic A, Migden MR, Oro AE, Dirix L, Lewis KD, Hainsworth JD, et al: Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med 366:2171-2179, 2012
84. Simon M, Boström JP, Hartmann C: Molecular genetics of meningiomas: from basic research to potential clinical applications. Neurosurgery 60:787-798, 2007
85. Simon M, Park TW, Leuenroth S, Hans VH, Löning T, Schramm J: Telomerase activity and expression of the telomerase catalytic subunit, hTERT, in meningioma progression. J Neurosurg 92:832-840, 2000
86. Simpson D: The recurrence of intracranial meningiomas after surgical treatment. J Neurol Neurosurg Psychiatry 20:22-39, 1957
87. Smith MJ, O'Sullivan J, Bhaskar SS, Hadfield KD, Poke G, Caird J, et al: Loss-of-function mutations in SMARCE1 cause an inherited disorder of multiple spinal meningiomas. Nat Genet 45:295-298, 2013
88. Smith MJ, Wallace AJ, Bennett C, Hasselblatt M, Elert-Dobkowska E, Evans LT, et al: Germline SMARCE1 mutations predispose to both spinal and cranial clear cell meningiomas. J Pathol 234:436-440, 2014
89. Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, et al: Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 366:707-714, 2012
90. Steilen-Gimbel H, Niedermayer I, Feiden W, Freiler A, Steudel WI, Zang KD, et al: Unbalanced translocation t(1;3)(p12-13;q11) in meningiomas as the unique feature of chordoid differentiation. Genes Chromosomes Cancer 26:270-272, 1999
91. Stott FJ, Bates S, James MC, McConnell BB, Starborg M, Brookes S, et al: The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J 17:5001-5014, 1998
92. Sun SQ, Cai C, Murphy RK, DeWees T, Dacey RG, Grubb RL, et al: Management of atypical cranial meningiomas, part 2: predictors of progression and the role of adjuvant radiation after subtotal resection. Neurosurgery 75:356-363, 2014
93. Sun SQ, Kim AH, Cai C, Murphy RK, DeWees T, Sylvester P, et al: Management of atypical cranial meningiomas, part 1: predictors of recurrence and the role of adjuvant radiation after gross total resection. Neurosurgery 75:347-355, 2014
94. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, et al: Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131:861-872, 2007
95. Tanzler E, Morris CG, Kirwan JM, Amdur RJ, Mendenhall WM: Outcomes of WHO Grade I meningiomas receiving definitive or postoperative radiotherapy. Int J Radiat Oncol Biol Phys 79:508-513, 2011
96. van Alkemade H, de Leau M, Dieleman EM, Kardaun JW, van Os R, Vandertop WP, et al: Impaired survival and longterm neurological problems in benign meningioma. Neuro Oncol 14:658-666, 2012
97. van den Munckhof P, Christiaans I, Kenter SB, Baas F, Hulsebos TJ: Germline SMARCB1 mutation predisposes to multiple meningiomas and schwannomas with preferential location of cranial meningiomas at the falx cerebri. Neurogenetics 13:1-7, 2012
98. Vernooij MW, Ikram MA, Tanghe HL, Vincent AJ, Hofman A, Krestin GP, et al: Incidental findings on brain MRI in the general population. N Engl J Med 357:1821-1828, 2007
99. Weber RG, Boström J, Wolter M, Baudis M, Collins VP, Reifenberger G, et al: Analysis of genomic alterations in benign, atypical, and anaplastic meningiomas: toward a genetic model of meningioma progression. Proc Natl Acad Sci U S A 94:14719-14724, 1997
100. Wen PY, Quant E, Drappatz J, Beroukhim R, Norden AD: Medical therapies for meningiomas. J Neurooncol 99:365-378, 2010
101. Witt H, Mack SC, Ryzhova M, Bender S, Sill M, Isserlin R, et al: Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma. Cancer Cell 20:143-157, 2011
102. Yang HW, Kim TM, Song SS, Shrinath N, Park R, Kalamarides M, et al: Alternative splicing of CHEK2 and codeletion with NF2 promote chromosomal instability in meningioma. Neoplasia 14:20-28, 2012
103. Yang SY, Park CK, Park SH, Kim DG, Chung YS, Jung HW: Atypical and anaplastic meningiomas: prognostic implications of clinicopathological features. J Neurol Neurosurg Psychiatry 79:574-580, 2008
104. Zhang X, Gejman R, Mahta A, Zhong Y, Rice KA, Zhou Y, et al: Maternally expressed gene 3, an imprinted noncoding RNA gene, is associated with meningioma pathogenesis and progression. Cancer Res 70:2350-2358, 2010